Vote Scores

Home / Companies / Stoke Therapeutics, Inc.

Company · votes reported on Form N-PXSTOK · SEC company no. 1623526

Stoke Therapeutics, Inc.

How funds and institutional managers reported voting their shares, year to 30 June 2026

Filers reporting
324year to 30 June 2026
Against management on pay
47.2%144 of 305 reporting filers
Same, by reported shares
31.8%shares reported on Form N-PX
Meetings on file
4across 3 seasons
48.4% for44.7% against6.8% other47.2% against management322 filers on say-on-pay

foragainstabstain, withhold or otheramber tick: the portion cast against management

324 Form N-PX filers reported votes at Stoke Therapeutics, Inc. for the year to 30 June 2026, across one meeting.

On the advisory vote on executive pay, 144 of the 305 filers that reported a position voted against management (47.2%), 40.6 percentage points above the median company on this site (6.6%). By reported shares the figure is 31.8% (median 2.9%). These are shares of the filers reporting on Form N-PX, not of all votes cast at the meeting.

Among the largest fund families, 25 voted with management on pay and 20 voted against: Fidelity, Northern Trust and FlexShares, DWS, Dimensional, American Century, Principal, Victory Capital and Allspring and others.

Meetings

Meeting dateSeasonFilers reportingItemsAgainst management on pay
3 Jun 2026year to 30 June 2026323347.2%
3 Jun 2025year to 30 June 2025211410.9%
5 Jun 2024year to 30 June 2024682not reported
24 Oct 2023year to 30 June 2024722not reported

Meetings with 20 or more reporting filers have their own page with every item. Dates are as filers typed them; dates up to three days apart are treated as one meeting.

Say-on-pay: this company and the median

year to 30 June 2026Stoke Therapeutics, Inc.Median company
Reporting filers voting against management47.2%6.6%
Reported shares voted against management31.8%2.9%

Among filers reporting on Form N-PX. The median is over 3,799 companies with a say-on-pay item reported by 20 or more filers.

How the largest families voted

Meeting of 3 Jun 2026: say-on-pay and each shareholder proposal that could be told apart.

FamilySay-on-pay
VanguardFor
BlackRock and iSharesFor
FidelityAgainst *
DimensionalAgainst *
State Street and SPDRAgainst *
American CenturyAgainst *
Franklin TempletonAgainst *
InvescoAgainst *
EquitableFor
Charles SchwabFor
Nuveen and TIAAFor
ProShares and ProFundsAgainst *
John Hancock and ManulifeAgainst *
Morgan Stanley, Eaton Vance and CalvertAgainst *
J.P. MorganFor
Goldman SachsFor
WisdomTreeFor
PGIM and PrudentialFor
Jackson National fundsAgainst *
Northern Trust and FlexSharesAgainst *
SEIFor
T. Rowe PriceFor
Lincoln FinancialAgainst
VoyaFor
First TrustAgainst
Russell InvestmentsFor
NationwideFor
Victory CapitalAgainst *
Brighthouse FundsFor
Guggenheim and RydexAgainst *
Columbia ThreadneedleAgainst *
BNY MellonFor
PrincipalAgainst *
Pacific Life fundsFor
Global XFor
MFSFor
TransamericaFor
Federated HermesFor
AllianceBernsteinAgainst *
Hartford FundsFor
DWSAgainst *
AllspringAgainst *
Harbor FundsFor
Janus HendersonAgainst *
Neuberger BermanFor
Artisan PartnersAgainst *

* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.

By season

SeasonFilers reportingAgainst management on pay, filersBy reported sharesSay-on-pay split
year to 30 June 202482not reportednot reported
year to 30 June 202521310.9%11.7%
year to 30 June 202632447.2%31.8%

Category mix

Share of the vote records reported for this company, by the category filers chose.

CategoryVote recordsShare
DIRECTOR ELECTIONS1,50946.3%
SECTION 14A SAY-ON-PAY VOTES1,11334.2%
AUDIT-RELATED50315.4%
COMPENSATION1243.8%
CAPITAL STRUCTURE100.3%

Questions

How did large funds vote at Stoke Therapeutics, Inc.?

For the year to 30 June 2026, 305 Form N-PX filers reported a say-on-pay vote at Stoke Therapeutics, Inc.; 144 voted against management (47.2%). The table on this page lists the position of each of the largest fund families on say-on-pay and on each shareholder proposal that could be told apart in the filings.

Were there shareholder proposals at Stoke Therapeutics, Inc.?

No proposal from security holders was reported by enough filers to be shown for the year to 30 June 2026.

Is this the meeting result?

No. The figures are shares of the funds and managers that file Form N-PX, and of the shares they reported. Holders that do not file the form (individuals, most foreign investors, insiders) are not included, so the split here can differ widely from the certified result, which Stoke Therapeutics, Inc. reports on Form 8-K.

Where does the data come from?

From Form N-PX filings on the SEC's EDGAR system, grouped by company. Filers type company names and meeting dates themselves; this site groups spellings of the same company and folds meeting dates up to three days apart. Data runs through 23 Sep 2026; the median compares 3,799 companies.

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings that list Stoke Therapeutics, Inc., grouped by company. The name is the most common spelling among filers; the ticker and SEC company number come from the SEC company tickers file, matched on the exact name. Not verified by the SEC. Filings read through 23 Sep 2026; page built 26 Sep 2026.